Research Analysts Set Expectations for OTLK Q2 Earnings

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – Stock analysts at HC Wainwright reduced their Q2 2025 EPS estimates for shares of Outlook Therapeutics in a research note issued on Tuesday, February 18th. HC Wainwright analyst D. Tsao now expects that the company will earn ($0.60) per share for the quarter, down from their previous forecast of ($0.58). HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($2.25) per share. HC Wainwright also issued estimates for Outlook Therapeutics’ Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($2.33) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at $0.62 EPS and FY2028 earnings at $2.37 EPS.

Outlook Therapeutics (NASDAQ:OTLK) last issued its quarterly earnings results on Friday, February 14th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.04).

Several other analysts have also recently weighed in on the company. Guggenheim reissued a “buy” rating and set a $12.00 price objective on shares of Outlook Therapeutics in a report on Friday, January 17th. BTIG Research dropped their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th. Finally, Chardan Capital reissued a “neutral” rating and set a $3.00 price objective on shares of Outlook Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.00.

Outlook Therapeutics Trading Down 0.9 %

Shares of NASDAQ OTLK opened at $1.70 on Thursday. Outlook Therapeutics has a 12-month low of $0.87 and a 12-month high of $12.85. The firm’s 50-day simple moving average is $1.88 and its 200 day simple moving average is $4.35.

Institutional Trading of Outlook Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Outlook Therapeutics by 49.2% in the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after acquiring an additional 112,812 shares during the last quarter. State Street Corp increased its stake in shares of Outlook Therapeutics by 10.0% in the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after acquiring an additional 21,201 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Outlook Therapeutics by 1,329.6% in the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock valued at $355,000 after acquiring an additional 174,896 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Outlook Therapeutics in the 4th quarter valued at about $246,000. Finally, Scotia Capital Inc. increased its stake in shares of Outlook Therapeutics by 124.4% in the 4th quarter. Scotia Capital Inc. now owns 73,989 shares of the company’s stock valued at $140,000 after acquiring an additional 41,023 shares during the last quarter. 11.20% of the stock is owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.